CD80 and liver dysplastic nodule: A recent study by Gagliardini et al, however, failed to demonstrate B7–1 expression in human and experimental DN, casting doubt on the applicability of abatacept, targeting podocyte B7–1, for the prevention or treatment of DN [5].